Trial Profile
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose of SHR4640 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruzinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Atridia
- 02 Jul 2018 Status changed from recruiting to completed.
- 12 Jan 2017 New trial record